Zynerba Pharmaceuticals (DB:6ZY) - Cotización, noticias y análisis

Resumen de acción 6ZY

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.

6ZY fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 97.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 67.21%

Los beneficios han crecido un 0.8% al año en los últimos 5 años

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Alta volatilidad del precio de la acción en los últimos 3 meses

Tiene menos de 1 año de cash runway

No tiene una capitalización de mercado significativa (€66M)

+ 2 riesgos adicionales

Competidores de Zynerba Pharmaceuticals, Inc.

Redx Pharma

DB:0RX

€65.0m

Apontis Pharma

XTRA:APPH

€68.8m

SynBiotic

DUSE:SBX

€43.1m

MPH Health Care

DB:93M1

€92.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Zynerba Pharmaceuticals
Historical stock prices
Current Share Price	US$1.23
52 Week High	US$1.42
52 Week Low	US$0.25
Beta	1.19
1 Month Change	3.36%
3 Month Change	362.41%
1 Year Change	91.02%
3 Year Change	-58.66%
5 Year Change	-80.87%
Change since IPO	-89.54%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	6ZY	DE Pharmaceuticals	Mercado DE
7D	0%	1.6%	-0.3%
1Y	91.0%	-26.4%	2.8%

Rentabilidad vs. Industria: 6ZY superó al sector German Pharmaceuticals , que obtuvo un rendimiento del -31.9% el año pasado.

Rentabilidad vs. Mercado: 6ZY superó al mercado German, que obtuvo un rendimiento del -0.3% el año pasado.

Volatilidad de los precios

Is 6ZY's price volatile compared to industry and market?
6ZY volatility
6ZY Average Weekly Movement	111.8%
Pharmaceuticals Industry Average Movement	7.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: El precio de las acciones de 6ZY ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 6ZY ha aumentado de 54% a 112% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2007	26	Armando Anido	www.zynerba.com

Resumen de fundamentos de Zynerba Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de Zynerba Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de 6ZY
Capitalización bursátil	€61.81m
Beneficios(TTM)	-€35.41m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-1.7x

Ratio precio-beneficio (PE)

¿Está 6ZY sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 6ZY
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$37.58m
Beneficios	-US$37.58m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.74
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado 6ZY a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 6ZY

Recompensas

Análisis de riesgos

Competidores de Zynerba Pharmaceuticals, Inc.

DB:0RX

€65.0m

XTRA:APPH

€68.8m

DUSE:SBX

€43.1m

DB:93M1

€92.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

New minor risk - Profitability

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Forecast to breakeven in 2025

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Insufficient new directors

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

New 90-day high: €4.07

New 90-day low: €2.69

Zynerba Pharmaceuticals, Inc. Provides Regulatory Update on Zygel™ in Fragile X Syndrome

New 90-day high: €3.33

New 90-day low: €2.80

Zynerba Pharmaceuticals, Inc. Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

First half earnings released

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from Russell Small Cap Completeness Index

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from Russell 3000 Growth Index

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Zynerba Pharmaceuticals, Inc.

0.0x

-1.7x

Beneficios e Ingresos